Bifogade filer
BONESUPPORT Q3 2025 EN
Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från BONESUPPORT Holding AB (publ) via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Large Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
2025-10-23 08:00:00
BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the third quarter 2025.
"Solid growth and new clinical evidence pave the way for continued success." Torbjörn Sköld, CEO
JULY - SEPTEMBER 2025
- Net sales increased by 24 percent (34 percent at constant exchange rates) and amounted to SEK 294.1 million (237.5).
- The US segment (previously named North America) reported a sales growth of 28 percent (40 percent at constant exchange rate).
- The Europe & Rest of the World (EUROW) segment reported a sales growth of 5 percent (7 percent at constant exchange rates).
- The gross margin amounted to 92.9 percent (92.9).
- The adjusted operating result¹ amounted to SEK 78.6 million (48.3). The reported operating result amounted to SEK 65.4 million (41.0).
- Earnings per share before and after dilution were SEK 0.52 (0.46)
JANUARY - SEPTEMBER 2025
- Net sales increased by 34 percent (41 percent at constant exchange rates) and amounted to SEK 862.1 million (641.7).
- The US segment reported a sales growth of 41 percent (49 percent at constant exchange rate).
- The Europe & Rest of the World (EUROW) segment reported a sales growth of 8 percent (10 percent at constant exchange rates).
- The gross margin amounted to 92.6 percent (92.6).
- The adjusted operating result amounted to SEK 180.7 million (125.9). The reported operating result amounted to SEK 149.9 million (101.9).
- Earnings per share before dilution were SEK 1.49 (1.22)
- Earnings per share after dilution were SEK 1.47 (1.20).
EVENTS DURING THE QUARTER
- During August, the Company announced that CMS has approved NTAP within open trauma for CERAMENT® G, providing additional hospital reimbursement within Medicare starting October 1, 2025.
- During September, strong results were published from a study that has been conducted at Stellenbosch University in South Africa. The study has demonstrated that CERAMENT G and CERAMENT® V can deliver the same excellent results for trauma patients with infection, in a developing market, as previously shown in studies at, among others, the Oxford Bone Infection Unit, UK.
- During September, positive results were published from a clinical study conducted at Charité in Berlin, demonstrating 100 percent infection referral for CERAMENT G in single-stage revision surgery for patients suffering from periprosthetic joint infection (PJI) of the hip.
- During September, Torbjörn Sköld started as CEO at BONESUPPORT. At the same time, former CEO Emil Billbäck transferred to a role as Senior Advisor.
EVENTS AFTER THE PERIOD
- Nothing to report.